A detailed history of Citigroup Inc transactions in Renovo Rx, Inc. stock. As of the latest transaction made, Citigroup Inc holds 384 shares of RNXT stock, worth $410. This represents 0.0% of its overall portfolio holdings.

Number of Shares
384
Holding current value
$410
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025

BUY
$0.9 - $1.43 $345 - $549
384 New
384 $0

Others Institutions Holding RNXT

About RenovoRx, Inc.


  • Ticker RNXT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,066,860
  • Market Cap $9.7M
  • Description
  • RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...
More about RNXT
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.